Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Recursion Q3 2025 Earnings Call - Leadership Transition and Platform Milestones Set Stage for Next Chapter
Recursion’s Q3 2025 earnings call marked a pivotal leadership transition with Najat Khan stepping in as CEO on January 1, while Chris Gibson remains chairman and advisor. The company boasts a robust c...
- Najat Khan named CEO effective January 1, with Chris Gibson transitioning to chairman and executive advisor role.
- Recursion holds a pro forma cash balance of approximately $785 million as of early October 2025, providing runway through end of 2027 without additional financing.
- Roche and Genentech partnership milestone: $30 million earned for delivering second whole genome microglia phenomap, advancing neuroscience drug discovery.
- +13 more takeaways
Royalty Pharma Q3 2025 Earnings Call - Strong Portfolio Growth and Strategic $1 Billion Capital Deployment
Royalty Pharma reported an 11% growth in portfolio and royalty receipts in Q3 2025, driven by a diversified and high-performing portfolio. The company deployed approximately $1 billion in capital on v...
- Royalty Pharma achieved 11% growth in portfolio receipts and recurring royalty cash flows in Q3 2025, underscoring steady top-line momentum.
- Full year 2025 portfolio receipts guidance was raised for the third time in the year to a range of $3.2 billion-$3.25 billion, reflecting 14-16% growth.
- Capital deployment reached approximately $1 billion in Q3 2025, including major acquisitions such as Amgen's Imdelltra royalty for up to $950 million.
- +7 more takeaways
Assurant Q3 2025 Earnings Call - Upgraded 2025 Outlook on Broad-Based Double-Digit Growth
Assurant delivered a strong Q3 2025 performance, marked by double-digit earnings growth across both Global Housing and Global Lifestyle segments. The company raised its full-year outlook, expecting lo...
- Assurant posted double-digit adjusted EBITDA and EPS growth in Q3 2025, excluding catastrophes, driven by strong performances in Global Housing and Global Lifestyle.
- The company raised its 2025 outlook to low double-digit adjusted EPS growth and nearly 10% adjusted EBITDA growth, surpassing initial expectations.
- Connected Living advanced with two new major partnerships: a multi-year reverse logistics and device repair agreement with a large U.S. mobile carrier, and a service contract partnership with Best Buy’s Geek Squad.
- +11 more takeaways
Champion Homes Q2 2026 Earnings Call - Strong Sales Growth Fueled by New Product Mix and Legislative Momentum
Champion Homes reported a robust second quarter with an 11% increase in net sales to $684 million and a 4% rise in homes sold, driven by strategic innovation in product offerings and expanding retail ...
- Q2 net sales rose 11% year-over-year to $684 million, with 6,771 homes sold, up 4% from prior year.
- Gross margin expanded 50 basis points to 27.5%, driven by product mix shift toward multi-section homes and higher captive retail sales percentage.
- Average selling price per home increased 7% in the U.S. to $98,700, reflecting more multi-section homes and pricing in company-owned retail centers.
- +12 more takeaways
ACM Research Q3 2025 Earnings Call - Innovation and Capital Raise Position Company for Long-Term Growth Despite Near-Term Shipment Headwinds
ACM Research reported a strong Q3 2025 with 32% revenue growth year-over-year reaching $269 million, setting a new quarterly record. The company highlighted robust demand driven by accelerating AI and...
- Revenue grew 32% YoY to a record $269 million in Q3 2025, reflecting strong demand across product portfolio.
- Shipment growth was modest at 1% YoY, with some customer pushouts and parts shortages delaying shipments into 2026.
- Gross margin was 42.1%, at the low end of guidance, impacted by product mix skewed to smaller front end tools and inventory write-downs.
- +13 more takeaways
Flowco Holdings Q3 2025 Earnings Call - Strong Margin Expansion and Rental Growth Offset Product Sales Decline
Flowco Holdings reported robust third quarter 2025 results highlighted by adjusted EBITDA of $76.8 million and a margin expansion of 382 basis points, driven largely by growth in its high-margin renta...
- Flowco delivered adjusted EBITDA of $76.8 million in Q3 2025, surpassing expectations with a 382 basis points margin expansion quarter-over-quarter.
- Free cash flow excluding recent acquisition capital stood at approximately $43 million, demonstrating cash flow durability.
- High margin rental portfolio growth in HPGL and VRU systems drove margin expansion and recurring contracted cash flows.
- +10 more takeaways
Aurora Cannabis Fiscal Q2 2026 Earnings Call - Profitable Global Medical Cannabis Growth with 69% Gross Margin
Aurora Cannabis reported a solid fiscal Q2 2026 with net revenue up 11% to $90 million, driven by a 15% increase in global medical cannabis sales and a 22% uptick in international revenue. The highlig...
- Aurora Cannabis net revenue rose 11% year-over-year to $90 million in fiscal Q2 2026.
- Global medical cannabis revenue hit a record, growing 15%, with international sales up 22%.
- Adjusted gross margin for medical cannabis climbed 700 basis points to 69%, surpassing the 60% target.
- +12 more takeaways
Hippo Q3 2025 Earnings Call - Strong Growth and Profitability Driven by Diversification and Underwriting Discipline
Hippo delivered a robust Q3 2025, posting a 33% year-over-year growth in gross written premium driven by diversification beyond homeowners into casualty and commercial lines. The insurer improved its ...
- Hippo grew gross written premium by 33% year over year to $311 million in Q3 2025.
- Adjusted net income reached $18 million, marking a $19 million improvement year over year.
- The company shifted to a unified carrier platform approach managing multiple insurance lines under one consolidated model.
- +12 more takeaways
Geron Corporation Q3 2025 Earnings Call - Rytelo Execution Reset and Growth Strategy Begins
Geron's Q3 2025 earnings call spotlighted a pivotal reset under new CEO Harout Semerjian and newly hired CCO Ahmed Al-Nawawi, emphasizing the path to expand Rytelo's commercialization in low-risk MDS....
- Rytelo net product revenue reached $47.2 million in Q3 2025, up significantly from $28 million in Q3 2024 but decreased 3% sequentially from Q2 2025 due to discontinuations, particularly in later-line patients.
- New patient starts in first and second line increased to 36% in Q3 from 30% in Q2, indicating progress in earlier-line adoption though overall demand remained flattish.
- Prescribing accounts expanded by 15% sequentially, adding 150 new ordering accounts to reach approximately 1,150 total, reflecting broader physician engagement.
- +7 more takeaways
Acacia Research Q3 2025 Earnings Call - Robust Portfolio Execution Amid Geopolitical and Macroeconomic Headwinds
Acacia Research reported strong third-quarter 2025 results highlighted by a 155% year-over-year revenue surge, primarily fueled by Deflecto's full integration. Despite ongoing tariff and economic pres...
- Acacia's total revenue reached $59.4 million in Q3 2025, marking a 16% sequential and 155% year-over-year increase, largely due to full-quarter contribution from Deflecto.
- Adjusted EBITDA for the company stood at $8 million with segment adjusted EBITDA at $12.6 million; free cash flow totaled $7.7 million despite a GAAP loss of $0.03 per share.
- Benchmark Energy, acquired via Revolution Assets in April 2024, maintains stable production with over 70% hedged through early 2028, mitigating downside commodity risks.
- +9 more takeaways